Patients with relapsed TB were defined as those previously treated for TB and declared “cured” or “treatment completed”, and currently diagnosed as Mtb positive by smears and cultures (n= 35). Patients with chronic TB were defined as those who had

started on a retreatment regimen after having failed previous treatment (n= 36). No patients had been reported to be MDR or XDR cases on the basis of drug sensitivity tests at the time of enrollment in this study. Thirty three healthy individuals (aged 21 to 54 years old, median = 36 years) recruited from the Blood Bank of Chiang Rai Hospital, Mae Chan Hospital and Phan Hospital were used as controls. They had no history suggestive of TB or other acute infectious diseases or diabetes selleck products at the time of enrollment. However, they were not subject to chest X-rays, TSTs or testing for latent TB infection and infection manifesting as active TB by IGRA upon enrollment. The ethical aspects of this study were approved by the Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand (Ref. No.3/2550) as part of a project studying multiple factors in recurrent TB, and written informed consent was obtained from all subjects. Before instituting anti-TB therapy, blood was collected aseptically in EDTA Vacutainers. Plasma and packed cells were separated by centrifugation www.selleckchem.com/products/epacadostat-incb024360.html and

stored at −80°C. HIV positive cases were excluded from the study by screening with the particle agglutination assay (Serodia-HIV-1/2, Fujirebio, Tokyo, Japan) and/or immunochromatographic rapid

test (Determine HIV-1/2, Abbott Laboratories, Champaign, IL, USA) or by ELISA (Enzygnost Anti-HIV 1/2 plus ELISA, Dade Behring, Marburg, Germany). Peripheral blood mononuclear cells from 75 pulmonary TB patients and 4 healthy PJ34 HCl controls were isolated by Ficoll-Hypaque density gradient centrifugation. In brief, 3 mL of whole blood in K3EDTA (Greiner Bio-One, Bangkok, Thailand) was diluted with an equal volume of PBS, mixed gently and layered carefully over 3 mL Ficoll-paque PLUS (Amersham Biosciences, Uppsala, Sweden). After centrifugation at 1000 g for 20 min at room temperature, the PBMCs were harvested. The supernatant was removed after centrifugation at 700 g for 10 min at 4°C and the pellet adjusted with RPMI 1640 containing 10% FBS. The viable PBMCs were counted in 0.2% Trypan blue. Approximately 1 × 106 PBMCs/mL in RPMI 1640 medium containing 10% FBS and 2-mercapto ethanol were added to each well of a 24 well plate, stimulated either with 20 μg/mL of PPD (Japan BCG laboratory, Kiyose, Japan) or heat killed Mtb (H37Ra) (Difco, Detroit, MI, USA) and incubated at 37°C in 5% CO2. The supernatants were harvested after 40 hr of stimulation, centrifuged at 1200 g for 3 min at 4°C and kept at −80°C. PMBCs stimulated with 20 μg/mL of PPD and not stimulated were used as positive and negative controls, respectively.